Key Takeaways
- AstraZeneca shares plunged up to 9% following disappointing late-stage trial results for its cardiac treatment Wainua
- The therapy failed to demonstrate its primary objective of lowering mortality and cardiovascular events in ATTR-CM patients during a 140-week study period
- More than half of study participants (57%) were using stabilizer medications at enrollment, potentially obscuring Wainua’s therapeutic effects
- Market experts point to structural issues in the trial protocol rather than drug efficacy problems, though questions about management credibility have emerged
- Ionis Pharmaceuticals shares declined 13.8% before market open; competitor Alnylam jumped 17%
AstraZeneca experienced a significant market setback on Thursday, with shares tumbling as much as 9.1% during London trading sessionsâmarking the pharmaceutical company’s steepest single-day decline since March 2020âafter its cardiac medication Wainua failed to achieve its primary objective in a crucial late-stage clinical study.
Shares trading on the New York Stock Exchange dropped 8.4% during premarket hours, erasing approximately ÂŁ23.3 billion ($31.21 billion) from the pharmaceutical giant’s total market capitalization at its daily nadir.
The experimental treatment underwent evaluation in 1,432 participants diagnosed with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), an uncommon medical condition characterized by the accumulation of misfolded protein deposits within cardiac tissue, ultimately impairing the heart’s blood-pumping capacity. Medical experts estimate between 300,000 and 500,000 individuals worldwide are affected by this condition.
Wainua did not demonstrate a statistically meaningful decrease in cardiovascular mortality and recurrent cardiac complications throughout the 140-week observation period when compared against a placebo group, AstraZeneca announced in a Thursday morning statement.
Questions Raised About Study Protocol
The outcome surprised market analysts. The majority had not anticipated a primary endpoint failure, particularly considering encouraging results from Amvuttra, a competing therapy developed by Alnylam Pharmaceuticals.
The core issue appears rooted in the trial’s structural framework. More than half the participants (57%) were already receiving stabilizer medication when the study commenced, with an additional 24% initiating stabilizer therapy during the research period. Because stabilizers operate through distinct mechanisms compared to Wainuaâclassified as a gene silencing agentâthe combination of both treatment approaches complicated efforts to isolate and quantify Wainua’s specific therapeutic contribution.
Among participants who had not begun stabilizer therapy at baseline, Wainua demonstrated a “nominally significant” positive effect. However, this subset analysis proved insufficient to satisfy the study’s principal objective.
Analysts from Jefferies noted that AstraZeneca “is meant to be able to have exceptionally good trial design ability,” suggesting that this design-related setback would negatively impact leadership credibility. The investment firm has revised downward its risk-adjusted sales projections for the drug by $2.5 billion.
BofA analyst Sachin Jain characterized the outcome as “a surprise,” observing that market participants had not even contemplated a failure scenario given the existing competitor performance data already available.
Future Outlook for Wainua Development
Barclays analysts predict AstraZeneca will decline to finance a new monotherapy clinical trial for Wainua, reasoning that such an approach would be unlikely to secure regulatory approval within this decade and would fall too far behind Alnylam’s already established market position.
Citi research analysts added that pursuing supplementary regulatory approvals for Wainua in the ATTR-CM indication now appears improbable, particularly since Alnylam’s Amvuttra already possesses authorization for treating this condition.
Wainua’s current regulatory authorization remains intact. The medication has already secured approval across more than 20 nations for treating polyneuropathyâa condition affecting nerve functionâand delivered $212 million in product sales for AstraZeneca during 2025.
Jefferies emphasized that this setback does not jeopardize AstraZeneca’s ambitious $80 billion annual revenue objective for 2030, which relies on launching up to 20 novel therapies. The research team noted the stock may remain under pressure until data from the AVANZAR oncology trial becomes available.
U.S.-traded partner Ionis Pharmaceuticals declined 13.8% in premarket trading. Alnylam advanced 17% while BridgeBio gained between 11% and 16%.
AstraZeneca stated the findings “support greater scientific understanding of treatment approaches” for individuals with ATTR-CM.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
